Table of Content

1.    US COVID-19 TESTING – CDC AND VENDOR ABILITY TO

PROVIDE TESTS        16
1.1    Covid-19 PCR Testing Market Driving Forces    16
1.2    Covid-19 Testing    25
1.3    Covid-19 Testing Equipment Missed the Mark    29
1.3.1    Covid-19    Need for Quarantine    31
1.3.2    Viral Load    31
1.3.3    Covid-19    Testing on Patients with Symptoms    32
1.3.4    Covid-19    Serological Contact Testing    34
1.3.5 Covid-19 Serological Testing on Social Contacts of Patients with Symptoms 35
1.4  Covid-19 Testing Prices    36

2.    DELAYS IN US COVID-19 TESTING AND INTERNATIONAL
RESPONSE    37
2.1    Broader Testing Delayed    37
2.2    Government and Open Market Control of Testing    37
2.3    Extracting Virus from Blood Sample    38

3.    COVID-19 TESTING REGIONAL ANALYSIS    39
3.1    Covid-19 Number People Affected Worldwide    39
3.2    US    40
3.3    China    44
3.4    India    46
3.5    Europe    47
3.6    Asia    49
3.7    Rest of World    49

4.    COVID-19 MOLECULAR DIAGNOSTICS TESTING TECHNOLOGY 50

4.1    Coronavirus Assay Testing Technique Polymerase Chain Reaction (PCR)    50
4.2    Panther Fusion Automates The Complex Steps Involved In Molecular    
Diagnostics Covid-19 Testing    52
4.2.1  Molecular Diagnostics    52
4.3    Scientists Need The Actual Virus In Order To Check A Diagnostic Test    53

5.    COVID-19 TESTING EQUIPMENT COMPANY PROFILES    55
5.1    Abbott Laboratories    55
5.2    Alphabet Verify    59
5.3    Astrotech    59
5.4    Beckman Coulter    60
5.5    Bill Gates    60
5.6    bioMérieux    61
5.7    Bodysphere    63
5.8  Center for Disease Control and Prevention CDC    64
5.8.1  CDC Serology Test for SARS-CoV-2    66
5.9    Co-Diagnostics, Inc.    66
5.10    Danaher    67
5.10.1    Cepheid is part of Danaher (NYSE:DHR).    68
5.10.2    Cepheid    68
5.10.3    Danaher / Integrated DNA Technologies (IDT)    69
5.11    US FDA    70
5.12    GenMark Diagnostics    70
5.13    Hologic    72
5.14    Hong Kong University of Science and Technology (HKUST)    73
5.15    LabCorp    74
5.15.1    LabCorp Testing    74
5.16    Logix Smart    74
5.17    Mammoth Biosciences    75
5.18    Opko / BioReference Laboratories    75
5.18.1    OPKO Health    76
5.19    Quidel    76
5.20    Quest Diagnostics    76
5.20.1    Quest / Roche Partnership    77
5.20.2    Roche IVD test / Quest Diagnostics LDT    78
5.21    Roche Diagnostics    79
5.21.1    Roche IVD Test for COVID-19 Offered by Quest Diagnostics    79
5.22    Sherlock Biosciences
5.23    SunSure Biotech
5.24    Tianjin University China
5.25    Thermo Fisher Scientific
5.25.1    Thermo Fisher Scientific / Applied Biosystems
5.25.2 Thermo Fisher / Dutch Diagnostics Firm Qiagen
5.26   Tianjin University of China.
5.27   Where to Look for More Covid-19 Information
6.    COVID-19 PCR TESTING: DESCRIPTION AND DYNAMICS
6.1    Rapidly Evolving COVID-19
6.2    COVID-19 a Respiratory Illness
6.2.1    Covid-19 Symptoms
6.2.2  Diagnostic Testing for COVID-19
6.2.3    Guidance for Testing
6.2.4    Covid-19 Quarantine
6.3    PCR and Molecular Diagnostic Testing Status
6.4    Where to get Tested
6.5    Testing: False Negative and False Positive
6.6    Serology Testing for COVID-19

List of Figures



Abstract: Covid-19 Testing Patients with Symptoms, Patients with No    
Symptoms and Serology Testing for Immunity and Quarantine Avoidance    1

Figure 1. US Covid-19 Serological Testing to see if a Person Has Already Had the Corona Virus and Does Not Need to Be Put in Quarantine, April 1 2020 to
September 1, 2020 Capability Forecasts by Two Week Intervals    12
Figure 2. US Serological Testing on People Who Have Been in Contact with    
Covid-19 Patients with Symptoms, May 1 to October 1, 2020    14
Figure 3. Covid-19 US Testing Market Driving Forces    17
Figure 4. Covid-19 Testing for Quarantine Implementation    19
Figure 5.    CDC and Vendor implementation of Covid-19 Testing    20
Figure 6.    Testing in the Next Phase of COVID-19 Outbreak: Suppression    21
Figure 7.    Covid-19 Characteristics Impacted by Testing    22
Figure 8.    Testing Characteristics Impacting Covid-19 Healthcare Management23

Figure 9. Covid-19 Testing Initially Quarantined Population Management Timelines 24

Figure 10.    Covid-19 Testing Second Wave Quarantined Population Management
Timelines    25            
Figure 11.    Impact on Testing of Waves of Critically Ill Patients with Covid-19    26
Figure 12.    US Covid-19 Testing Equipment Market Share Description, Number of
Tests Day, Tests per Week Capability, Time to Administer, April 1, 2020    27
Figure 13.    US Covid-19 Testing Equipment Company Description, Number of    
Tests per Day, Tests per Week Capability, April 1, 2020, Time to Administer,    
April 1, 2020        29
Figure 14.    US Covid-19 Patient with Symptom Testing Capability April 1 2020 to
September 1, 2020 Forecasts by Two Week Intervals, Testing Patients Who    
Present Symptoms at Care Facility or Hospital    34
Figure 15. US Serological Testing on People Who Have Been in Contact with    
Covid-19 Patients with Symptoms, May 1 to October 1, 2020    36
Figure 16. Abbott Virus Detection Machine    57
Figure 17.    GenMark Diagnostics Coronavirus ePlex Testing System    72
Figure 18.    Hologic’s Panther Fusion® SARS-CoV-2 test    73
Figure 19.    Quest Healthcare Provider Fact Sheet    80
Figure 20.    Governor Cuomo - The Face of COVID-19 Resistance    87